Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease (Q57911462)

From Wikidata

Jump to navigation Jump to search

scientific article published in June 2012

Language	Label	Description	Also known as
English	Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease	scientific article published in June 2012

Statements

scholarly article

0 references

Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease (English)

0 references

0 references

1 reference

based on heuristic

inferred from title

chronic renal insufficiency

1 reference

based on heuristic

inferred from title

chronic heart failure

1 reference

based on heuristic

inferred from title

Mihai Gheorghiade

3

object named as

Mihai Gheorghiade

0 references

Piotr Ponikowski

object named as

Piotr Ponikowski

6

0 references

10

object named as

Faiez Zannad

0 references

1

object named as

Bertram Pitt

0 references

Gerasimos Filippatos

2

object named as

Gerasimos Filippatos

0 references

4

object named as

Lars Kober

0 references

5

object named as

Henry Krum

0 references

Christina Nowack

7

object named as

Christina Nowack

0 references

8

object named as

Peter Kolkhof

0 references

author name string

So-Young Kim

9

0 references

publication date

June 2012

0 references

European Journal of Heart Failure

0 references

14

0 references

6

0 references

668-675

0 references

A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS061

21 January 2018

CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the cornerstone of therapy for systolic heart failure.

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS061

21 January 2018

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS061

21 January 2018

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS061

21 January 2018

Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS061

21 January 2018

Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS061

21 January 2018

Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS061

21 January 2018

Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS061

21 January 2018

Mineralocorticoid receptor blockers and chronic kidney disease

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS061

21 January 2018

A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome.

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS061

21 January 2018

Use of aldosterone antagonists in heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS061

21 January 2018

Heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF.

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS061

21 January 2018

EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot).

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS061

21 January 2018

Antiandrogenic Effect of Spirolactones: Mechanism of Action

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS061

21 January 2018

Aldosterone in congestive heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS061

21 January 2018

Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS061

21 January 2018

A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS061

21 January 2018

Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS061

21 January 2018

Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS061

21 January 2018

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS061

21 January 2018

A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS061

21 January 2018

Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS061

21 January 2018

A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS061

21 January 2018

The frequency of hyperkalemia and its significance in chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS061

21 January 2018

Identifiers

10.1093/EURJHF/HFS061

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57911462&oldid=1833600306"